Merck Eyes Emerging Biosimilars Market In Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's Japanese subsidiary Banyu Pharmaceutical has started domestic trials for its generic erythropoietin, poised to be Merck's first biosimilar launch.
You may also be interested in...
Daiichi Sankyo Generics Entry Could Help Japan's Branded Generics Makers
Following Pfizer's step, Daiichi Sankyo is venturing into the generic drug business in Japan. The third-largest domestic branded drug maker Feb. 26 announced the establishment of generic subsidiary Daiichi Sankyo Espha, and a plan to start marketing products beginning in October. The announcement has stirred up a shock wave across the industry
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan
Merck Adds Biosimilar Capabilities, Insmed Gets Fresh Start In $130M Deal
A virtually broke biotech finds itself flush with cash while a major pharma's recently launched follow-on biologics play now enjoys an expanded pipeline and increased research and manufacturing capabilities - that's the outcome of a transaction labeled "a win/win for both parties" by Insmed CEO Geoffrey Allan